Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S.-China Hybrid Ascletis Helps Forge Stronger Ties Between China And North Carolina

This article was originally published in PharmAsia News

Executive Summary

U.S.-China hybrid Ascletis Inc. has reinforced ties between China and the U.S. under a memorandum of understanding signed July 16 with the Hangzhou Hi-Tech Industry Development Zone in Zhejiang Province, China, and The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina
Advertisement

Related Content

Ascletis Strategy Begins To Reach Fruition In Deal With Alnylam For HCC Candidate
Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing
Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
Ascletis Raises $100MM To Deploy Its U.S.-China Hybrid Drug Development Model
Yangtze Delta Expected To Be Largest CRO Cluster By 2015
Advertisement
UsernamePublicRestriction

Register

SC078586

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel